The long road of biopharmaceutical drug development: From inception to marketing

QJM: An International Journal of Medicine

Volumn 103, Issue 1, 2009, Pages 3-7

  Mundae, M K ^a   Ostor A J K ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY;

CLINICAL STUDY; DRUG APPROVAL; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG MARKETING; DRUG PACKAGING; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; GENE MAPPING; HISTORY OF MEDICINE; HUMAN; IMMUNOGENICITY; LICENSING; NOMENCLATURE; NONHUMAN; PHARMACODYNAMICS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REVIEW; TOXICITY TESTING; WORLD HEALTH ORGANIZATION;

EID: 77950318165     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcp145     Document Type: Review

References (18)

1. Steinmeyer D, McCormick E. The art of antibody process development. Drug Discov Today 2008; 13:13-4.
2. Mascelli M, Zhou H, Sweet R, Getsy J, Davis H, Graham M, et al. Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development. J Clin Pharmacol 2007; 47:553-67.
3. Roger S, Goldsmith D. Biosimilars: it's not as simple as cost alone. J Clin Pharm Ther 2008; 33:459-64.
4. Fleming A. Classics in infectious diseases: on the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae by Alexander Fleming, reprinted from the British Journal of Experimental Pathology 10:226-236, 1929. Rev Infect Dis 1980; 2:129-39.
5. Schwaber J, Cohen, EP. Human x mouse somatic cell hybrid clones secreting immunoglobulins of both parental types. Nature 1973; 244:444-7.
6. Leget G, Czuczman M. Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol 1998; 10:546-51.
7. Drug Discovery and Development. Technology in Transition. Chapter 18 Easedale and Vose. Churchill Livingstone, Elsevier, 2006.
8. Roque A, Lowe C, Taipa M. Antibodies and genetically engineered related molecules: production and purification. Biotech Prog 2004; 20:639-54.
9. Gatto B. Biologics targeted at TNF: design, production and challenges. Reumatismo 2006; 58:94-103.
10. t'Hart BA, Amor S, Jonker M. Evaluating the validity of animal models for research into therapies for immunebased disorders. Drug Discov Today 2004; 9.
11. t'Hart BA, Vervoordeldonk M, Heeney J, Tak P. Gene therapy in nonhuman primate models of human autoimmune disease. Gene therapy 2003; 10:890-901.
12. Inside Innovation: The Drug Discovery Process. Available at http://www.innovation.org.
13. http://www.fda.gov.
14. Howland R. How are drugs approved? Part 3. The stages of Drug Development. J Psychosoc Nursing 2008; 46:17-20.
15. http://www.emea.europa.eu/htms/aboutus/emeaoverview.htm.
16. Gundersen L. The complex process of naming drugs. Annals of Internal Medicine 1998; 129:677-8.
17. Kenagy J, Stein G. Naming, labeling and packaging of pharmaceuticals. Am J Health-Syst Pharm 2001; 58:2033-41.
18. Bumol T, Watanabe A. Genetic information, genomic technologies and the future of drug discovery. JAMA 2001; 285:551-5.